Lyell Immunopharma Inc LYEL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 05/16/24 EDT
2.78quote price arrow up+0.17 (+6.51%)
Volume
619,762
52 week range
1.32 - 3.97
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.78
  • 52 Week High3.97
  • 52 Week High Date06/16/23
  • 52 Week Low1.32
  • 52 Week Low Date10/09/23

Key Stats

  • Market Cap708.731M
  • Shares Out254.94M
  • 10 Day Average Volume0.70M
  • Dividend-
  • Dividend Yield-
  • Beta-0.55
  • YTD % Change34.54

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.78
  • 52 Week High3.97
  • 52 Week High Date06/16/23
  • 52 Week Low1.32
  • 52 Week Low Date10/09/23
  • Market Cap708.731M
  • Shares Out254.94M
  • 10 Day Average Volume0.70M
  • Dividend-
  • Dividend Yield-
  • Beta-0.55
  • YTD % Change34.54

RATIOS/PROFITABILITY

  • EPS (TTM)-0.91
  • P/E (TTM)-3.07
  • Fwd P/E (NTM)-3.47
  • EBITDA (TTM)-219.78M
  • ROE (TTM)-32.93%
  • Revenue (TTM)68,000.004
  • Gross Margin (TTM)-
  • Net Margin (TTM)-335,794.09%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Lyell Immunopharma Inc

 

Profile

MORE
Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with...
Richard Klausner M.D.
Chairman of the Board
Lynn Seely M.D.
President, Chief Executive Officer, Director
Stephen Hill
Chief Operating Officer
Charles Newton
Chief Financial Officer
Richard Goold M.D.
Chief Information Officer
Address
201 Haskins Way, Suite 301
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
ITOS
Iteos Therapeutics Inc
17.90-0.06-0.33%
SVRA
Savara Inc
4.72-0.11-2.28%
ORIC
Oric Pharmaceuticals Inc
9.02-0.29-3.11%
LXRX
Lexicon Pharmaceuticals Inc
1.84-0.10-5.15%
GHRS
GH Research PLC
12.73-0.01-0.08%